Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 6,311 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Advanced therapy Clear all

Conditions: Breast Cancer
Interventions: Fulvestrant with Enzalutamide; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Lone Tree, Colorado • Germantown, Tennessee

Conditions: Hepatocellular Carcinoma
Interventions: TheraBionic Device, Placebo Device; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Winston-Salem, North Carolina

Conditions: Decision Support Techniques
Interventions: CHAMPION; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Baltimore, Maryland • Charlottesville, Virginia • Richmond, Virginia

Conditions: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
Interventions: TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin; Combination Product
Lead sponsor: TORL Biotherapeutics, LLC; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Fullerton, California • Irvine, California • Los Angeles, California + 3 more

Conditions: Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions: c-Met inhibitor AMG 337, placebo, oxaliplatin, leucovorin calcium, fluorouracil, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
Interventions: paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment; Drug · Radiation · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions: M7824, M9241, SBRT; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastrointestinal Cancer
Interventions: DB-1324; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Port Saint Lucie, Florida • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more

Conditions: Cancer, Anxiety
Interventions: Health Education Program, CBT Mobile Application; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma, Skin Cancer
Interventions: BMS-986205, Nivolumab, Placebo; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Miami Beach, Florida + 3 more

Conditions: Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Antiandrogen Therapy, Apalutamide, Biopsy, Niraparib, Prednisone, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer
Interventions: Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT); Drug · Radiation
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 50
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Solid Tumor
Interventions: BS006 Injection; Drug
Lead sponsor: Binhui Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Detroit, Michigan

Conditions: Knee Osteoarthritis
Interventions: Synvisc-One Injection, Sham Injection; Device · Other
Lead sponsor: Elaine Husni; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Pancreatic Cancer
Interventions: Enzalutamide, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cervical Cancer, Vaginal Cancer
Interventions: therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 169
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: benzoylphenylurea; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Malignant Solid Tumor
Interventions: RPTR-1-201, PD-1 / PD-L1 monoclonal antibody; Drug
Lead sponsor: Repertoire Immune Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Lake Success, New York • San Antonio, Texas

Conditions: Lung Cancer
Interventions: Erlotinib, Bevacizumab; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more

Conditions: Triple Negative Breast Cancer, Residual Disease
Interventions: Tetrathiomolybdate, Capecitabine, Pembrolizumab; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 3
States / cities: Indianapolis, Indiana • Lebanon, New Hampshire • New York, New York

Conditions: Colorectal Cancer
Interventions: semaxanib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 10
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 31
States / cities: Bakersfield, California • Duarte, California • Fullerton, California + 27 more

Conditions: Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: docetaxel, cisplatin, carboplatin, fluorouracil, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma

Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

Mobile App of CBT for Anxiety and Cancer

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

Optimization of Synvisc-One for Knee OA

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Benzoylphenylurea in Treating Patients With Advanced Solid Tumors

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)